Immunologic aspects of BCG-mediated regression of established tumors and metastases in guinea pigs.
D000818:Animals; D000917:Antibody Formation; D000961:Antilymphocyte Serum; D001500:BCG Vaccine / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy; D004912:Erythrocytes / Q000276:immunology; D006084:Graft Rejection; D006168:Guinea Pigs; D006644:Histiocytes / Q000648:ultrastructure; D007109:Immunity; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009374:Neoplasms, Experimental; D012075:Remission, Spontaneous; D016038:Skin Transplantation; D014184:Transplantation, Homologous; D014374:Tuberculin Test
D000961:Antilymphocyte Serum; D001500:BCG Vaccine